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Abstract
Background
Cancer of unknown primary (CUP) is a late-stage malignancy with poor prognosis, but we
know little about what diagnostic tests and procedures people with CUP receive prior to
diagnosis. The purpose of this study was to determine how health service utilisation prior to
diagnosis for people with cancer-registry notified CUP differs from those notified with meta-
static cancer of known primary.
Methods
We identified people with a cancer registry notification of CUP (n = 327) from the 45 and Up
Study, a prospective cohort of 266,724 people�45 years in New South Wales, Australia,
matched with up to three controls with a diagnosis of metastatic cancer of known primary (n
= 977). Baseline questionnaire data were linked to population health data to identify all
health service use, diagnostic tests, and procedures in the month of diagnosis and 3 months
prior. We used conditional logistic regression to estimate adjusted odds ratios (ORs) and
95% confidence intervals (CIs).
Results
After adjusting for age and educational attainment, people with a cancer-registry notified
CUP diagnosis were more likely to be an aged care resident (OR = 2.78, 95%CI 1.37–5.63),
have an emergency department visit (OR = 1.65, 95%CI 1.23–2.21), serum tumor marker
tests (OR = 1.51, 95%CI 1.12–2.04), or a cytology test without immunohistochemistry (OR
= 2.01, 95%CI 1.47–2.76), and less likely to have a histopathology test without immunohis-
tochemistry (OR = 0.43, 95%CI 0.31–0.59). Neither general practitioner, specialist, allied
health practitioner or nurse consultations, hospitalisations, nor imaging procedures were
associated with a CUP diagnosis.
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Conclusions
The health service and diagnostic pathway to diagnosis differs markedly for people notified
with CUP compared to those with metastatic cancer of known primary. While these differ-
ences may indicate missed opportunities for earlier detection and appropriate management,
for some patients they may be clinically appropriate.
Introduction
Cancer of unknown primary site (CUP) is the 14th most commonly diagnosed cancer and the
6th most common cause of cancer death in Australia.[1] It is characterized by metastatic dis-
ease with an unidentified primary site, and extremely poor survival;[2–5] in Australia, the
5-year survival rate is 13%.[6] Population-based CUP incidence rates have declined over time,
[2,6,7] a trend that can most likely be attributed to advances in diagnostic investigations.
While a diagnosis of CUP ideally should be limited to people with a histological confirmation
of metastatic cancer, in whom thorough testing has failed to identify the site of the primary
tumor, people registered with a diagnosis of CUP in population-based cancer registries are
heterogeneous, with many people receiving a diagnosis based on clinical examination only.
[4,5,8–11] Thus, it is difficult to compare population-based studies of registry-notified CUP
to cases series of “true CUP” cases, who have received exhaustive investigations.
Studies of how people diagnosed with CUP interact with the health system prior to their
definitive diagnosis, and what investigations they receive, are limited.[8,12] Although there are
no Australian CUP clinical practice guidelines, the US National Comprehensive Cancer Net-
work (NCCN) and the European Society for Medical Oncology (ESMO) CUP-specific guide-
lines support the judicious use of diagnostic investigations, in keeping with a patient’s prognosis
and treatment options.[13,14] Yet, the diagnostic pathway of patients with a cancer-registry
notified CUP diagnosis is highly variable,[8,15,16] which may reflect heterogeneity in clinical
presentation and patient characteristics.
Previous studies suggest that the diagnostic pathway for people with CUP differs compared
to people diagnosed with other cancers, including late-stage cancers of known primary site.[8]
CUP appears more likely to be diagnosed following an emergency department visit compared
with all other cancers, and diagnosis may involve less specialist input and fewer invasive diag-
nostic procedures, including histopathological diagnosis of cancer.[8,15] In this prospective
Australian cohort study, we sought to compare the pathway to diagnosis for people diagnosed
with a cancer-registry CUP diagnosis, compared with people diagnosed with metastatic cancer
of known primary site.
Materials and methods
Data sources
The Sax Institute’s 45 and Up Study[17] is a prospective cohort study with comprehensive
information on self-reported lifestyle behaviors and a range of health, functional and social
measures at baseline. New South Wales (NSW) residents aged at least 45 years were randomly
sampled from the Department of Human Services (formerly Medicare Australia) enrollment
database, which provides near complete coverage of the population. People 80+ years of age
and residents of rural and remote areas were oversampled. A total of 266 933 individuals
joined the study by completing a postal questionnaire between 2006 and 2009. The date of
completion of the questionnaire was considered the baseline period. Around 18% of those
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invited participated, and the cohort included 11% of the NSW population aged 45 years or
more.
Australia’s publicly funded health care system provides all citizens and permanent residents
with a range of health services including treatment in public hospitals, subsidized treatment in
private hospitals, subsidized outpatient services including consultations, procedures and tests,
and subsidized medicines. Records of these transactions are made available for ethically
approved health research. The 45 and Up Study cohort was probabilistically linked to popula-
tion-based administrative health datasets by the Centre for Health Record Linkage to identify
incident cancers, comorbid health conditions, subsidized health services and deaths. The data-
sets were: (i) the NSW Cancer Registry, a population-based registry of incident invasive cancer
diagnoses (excluding basal and squamous cell carcinoma of the skin) in NSW 1994–2012; (ii)
the NSW Admitted Patients Data Collection 2001–2015; (iii) the NSW Emergency Depart-
ment Data Collection 2005–2016; (iv) the Medicare Benefits Scheme (MBS) 2001–2015; (v)
the Pharmaceutical Benefits Scheme (PBS) 2004–2015; and (vi) the NSW Registry of Births,
Deaths and Marriages 2006–2016. We excluded 209 cohort participants because they did not
have a linked MBS or PBS record.
Study population
As previously described, we defined cases as cohort participants with a cancer registry diagno-
sis of CUP (ICD-10-AM codes C80, C76, C26 or C39) more than 3 months after baseline.
[18,19] We included all people with a registry diagnosis of CUP, regardless of whether it was
histopathologically confirmed. We randomly selected a control group with a cancer registry
diagnosis of solid metastatic cancer of known primary site; for the controls, the first manifesta-
tion of this cancer was metastatic disease, with a recorded extent of disease spread that was
either distant or regional, on the basis of the highest degree of spread (extent of spread of can-
cer from its point of origin) classified by the NSW Cancer Registry. Individuals with another
registered cancer diagnosis in the same month were also eligible for inclusion as a case or
control.
We matched the controls to cases by month and year of completion of the baseline ques-
tionnaire in the cohort and by month and year of cancer diagnosis. We selected up to three
controls per case using incidence density sampling with replacement.[20] We did not match
on age and sex as we wished to examine the effect of these factors.
Health service use
We quantified health services accessed in the month of diagnosis and the three months prior
to diagnosis, including hospitalisations, emergency department (ED) visits, and consultations
with general practitioners (GP), specialists, allied health practitioners, and nurses, and resi-
dence in an aged care facility. As the NSW Cancer Registry only provides the month and year
of cancer diagnosis, we ascertained all health services in the entire month of diagnosis. We
focused on the month of diagnosis and the three months prior to diagnosis based on our previ-
ous work showing that health service utilisation increased around this time [8], and clinical
advice that this was the most relevant time period for diagnostic investigation. We confirmed
that these observations held true for our cohort (data not shown).
We also identified the subset of GP consultations in the home, an institution or hospital
(MBS item numbers 4, 24, 37, 47, 58, 59, 60, 65, 5003, 5023, 5043, 5063, 5220, 5223, 5227,
5228) as a marker of patient frailty; we also distinguished GP consultations that occurred in
the doctors’ rooms (doctor’s offices) (MBS item numbers 2, 3, 23, 35, 36, 44, 52, 53, 54, 57,
2501, 2504, 2517, 2521, 2525, 2546, 2552, 2721, 2725, 5000, 5020, 5040, 5060). We further
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distinguished GP consultations for the preparation, contribution or review of a GP manage-
ment plan or multidisciplinary/team care plan (MBS item numbers 721, 723, 729, 731, 732,
735, 739, 743, 747, 750, 758, 820, 822, 823, 825, 826, 828, 830, 832, 834, 835, 837, 838, 900). We
separately identified specialist consultations for the initial assessment or review of patients
with at least two comorbidities, classified as complex cases (MBS item numbers 132, 133). All
health service use variables were dichotomized (any vs none).
Diagnostic tests and procedures
We ascertained all cancer-related imaging, endoscopy, medical procedures and pathology
tests performed in tertiary and community settings during the month of diagnosis and the
three months prior. We identified X-rays, computerized tomography (CT) scans, single pho-
ton emission computerized tomography (SPECT), ultrasound, magnetic resonance imaging
(MRI), nuclear imaging and endoscopy. We classified medical procedures as exploratory sur-
gery, non-surgical resection (such as fine needle aspiration, biopsy), and surgical resection
(both non-cutaneous and cutaneous). The pathology tests of interest were one or more serum
tumor markers (beta-2 microglobulin, alpha-fetoprotein, ca-15.3 antigen, ca-125 antigen, ca-
19.9 antigen, cancer associated serum antigen, carcinoembryonic antigen, human chorionic
gonadotrophin, neuron specific enolase, thyroglobulin, and prostate specific antigen; MBS
item numbers 66629, 66650, 66651, 66652, 66653, 66655), cytology and histopathology alone
or with immunostaining (immunocytochemistry or immunohistochemistry), and cytogenet-
ics. These tests are most commonly used to help identify the tissue of origin for CUP.[14,21]
Statistical analysis
We used conditional logistic regression to estimate the odds of a cancer-registry notified CUP
diagnosis associated with health service use and diagnostic tests and procedures. We first mod-
elled each factor individually adjusted by age and sex only, and those variables with p<0.20
were considered for inclusion in the fully adjusted multivariable model. We used the 45 and
Up Study baseline questionnaire to identify potential confounding factors, such as self-
reported overall health and thus fitness for diagnostic investigation. To avoid multicollinearity
between similar measures, we assessed the association between pairs of factors using Crame´r’s
V statistic and those with a correlation coefficient�0.25 were considered correlated. This
approach was also used to identify tests and procedures that were on the pathway between
consultations and visits and a cancer diagnosis, to avoid over-adjustment.
We built conditional logistic regression models using backward elimination, stopping when
the remaining variables in the model were all significantly associated with CUP (p<0.05). We
built multiple multivariable models with all possible combinations of non-correlated variables,
and then selected the model with the lowest Akaike Information Criterion as the final model.
Ethics
The study was approved by the NSW Population and Health Services and Human Research
Ethics Committee (2012/11/428) and the 45 and Up Study was approved by the University of
New South Wales Human Research Ethics Committee (HREC 15408). All participants pro-
vided written informed consent at the time of recruitment for follow-up and linkage of their
information to administrative health databases. All procedures were in accordance with the
ethical standards of the ethics committees mentioned above and with the 1964 Helsinki decla-
ration and its later amendments.
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Results
We identified 327 incident cases of CUP and 977 matched incident solid metastatic cancer
controls, diagnosed between 2006 and 2012. The median age at diagnosis of CUP was 76 years
(interquartile range, IQR: 66–82 years) and 68 years (IQR: 60–76 years) for solid metastatic can-
cer controls. The median time from completion of the baseline questionnaire to cancer diagno-
sis was 33 months (IQR: 21–46 months). Of the people with a registry-notified CUP diagnosis,
165 (50.5%) had a histopathogical diagnosis, 49 (15.0%) a cytological diagnosis (including fine
needle aspiration, smears, washing and sputum), 88 (26.9%) a clinical diagnosis (including clin-
ical, imaging and biochemical procedures) and 25 (7.6%) were identified by death certificate
only. Of the CUP cases (n = 165) registered with a NSW Cancer Registry histopathological diag-
nosis, 20 (12.1%) tumors were carcinoma (subtype not specified), 81 (49.1%) were carcinoma
(subtype specified), 50 (30.3%) were adenocarcinoma, and 14 (8.5%) were other morphological
types. Of the 870 people with metastatic cancer of known primary with a histopathological diag-
nosis, 407 (46.8%) tumors were carcinoma, 395 (45.4%) were adenocarcinoma, and 68 (7.8%)
were other. The most common primary sites for the solid metastatic cancer controls were breast
(C50; n = 168), bronchus and lung (C34; n = 163), colon (C18; n = 152), prostate (C61; n = 123)
and rectum (C20; n = 57).
In the month of diagnosis and the three months prior, people with a cancer-registry notified
CUP diagnosis were more likely to have an ED visit (odds ratio, OR = 1.84, 95% confidence
interval, CI 1.41–2.40) and less likely to have a specialist consultation (OR = 0.66, 95%CI 0.48–
0.92), compared to solid metastatic cancer controls (Table 1) in models adjusted for age and
sex only. During this period there was no difference between the two metastatic cancer groups
in terms of hospitalisation or consultations with a GP, allied health practitioner, nurse, or spe-
cialist indicating complex care. People diagnosed with CUP were more than 3-fold more likely
Table 1. Association between recent health service use and diagnosis of CUP compared to metastatic cancer of known primary.
Health service use in three months prior and month of
diagnosis
CUP (n = 327) Metastatic cancer, known primary site
(n = 977)
Age- and sex-adjusted OR (95%
CI)
n (%) n (%)
Tertiary care
Hospitalisation 221 (67.6) 682 (69.8) 0.88 (0.66–1.17)
Emergency department visit 172 (52.6) 316 (32.3) 1.84 (1.41–2.40)
Consultations
General practitioner (GP) 305 (93.3) 932 (95.3) 0.79 (0.44–1.42)
Consulting room (including after-hours visits)a 297 (90.8) 920 (94.2) 0.78 (0.47–1.29)
Home, institution or hospital (including after-hours
visits)b
49 (15.0) 79 (8.1) 1.43 (0.96–2.13)
Management and multidisciplinary care plans 64 (19.6) 143 (14.6) 1.27 (0.91–1.78)
Specialist/consultant physician 244 (74.6) 825 (84.4) 0.66 (0.48–0.92)
Complex case 51 (15.6) 121 (12.4) 1.30 (0.89–1.90)
Allied health practitioner 82 (25.1) 245 (25.1) 0.96 (0.71–1.31)
Nurse 39 (11.9) 127 (13.0) 0.84 (0.56–1.26)
Residence in aged care facilityc 32 (9.8) 19 (1.9) 3.42 (1.78–6.56)
a MBS item numbers 2, 3, 23, 35, 36, 44, 52, 53, 54, 57, 2501, 2504, 2517, 2521, 2525, 2546, 2552, 2721, 2725, 5000, 5020, 5040, 5060.
b MBS item numbers 4, 24, 37, 47, 58, 59, 60, 65, 5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228.
c EDDC referral source = 5 (Residential Aged Care facility); APDC: source of referral 6 (Nursing home/Residential Aged Care Facility) or mode of separation = 3
(transferred to nursing home) or peer group = F2 (Nursing home) and MBS item numbers: 20, 35, 43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267,
2125, 2138, 2179, 2220, 82223, 82224, 82225, 73934, 73935, 10984, 903, 731.
https://doi.org/10.1371/journal.pone.0230373.t001
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to be in aged care (OR = 3.42, 95%CI 1.78–6.56). We found people diagnosed with CUP were
less likely than controls to have an endoscopy, a surgical (non-cutaneous) resection, and histo-
pathology (Table 2). Conversely, they were more likely to have serum tumor marker tests and
cytology. Overall, 21 (6.4%) people diagnosed with CUP did not have any cancer-related inves-
tigations, as defined by imaging procedures, endoscopy, medical procedures (e.g. resection),
or pathology tests. Among controls, 60 (6.1%) did not have any cancer-related investigations.
In our fully adjusted model, the only confounding factors were age and educational attain-
ment, with those diagnosed with CUP more likely to be older and to have no school certificate
(less than 4 years of secondary education) (Table 3).[18] After adjustment for these factors,
and the mutual adjustment for health service use, diagnostic tests and procedures, the only var-
iables that remained associated with an increased probability of a CUP diagnosis were being in
an aged care facility (OR = 2.78, 95%CI 1.37–5.63),�1 ED visit (OR = 1.65, 95%CI 1.23–2.21),
and the following pathology tests: serum tumor marker tests (OR = 1.51, 95%CI 1.12–2.04),
and cytology without immunohistochemistry (OR = 2.01, 95%CI 1.47–2.76). People diagnosed
with CUP were less than half as likely to have had a histopathology test without immunohis-
tochemistry (OR = 0.43, 95%CI 0.31–0.59).
Discussion
In a contemporary cohort of Australian adults, we observed differences in the pathways to
diagnosis for people with a cancer-registry notified CUP diagnosis compared with people
Table 2. Association between recent cancer-related diagnostic tests and procedures and diagnosis of CUP compared to metastatic cancer of known primary.
Tests or procedures in month of diagnosis and three months
prior
CUP (n = 327) Metastatic cancer, known primary
(n = 977)
Age- and sex-adjusted OR (95%
CI)
n (%) n (%)
Imaging procedures
X-ray 165 (50.5) 493 (50.5) 0.99 (0.76–1.29)
Computerized tomography (CT) 213 (65.1) 618 (63.3) 1.17 (0.89–1.55)
Single photon emission computerized tomography (SPECT) 49 (15.0) 159 (16.3) 1.17 (0.81–1.69)
Ultrasound 141 (43.1) 436 (44.6) 1.24 (0.94–1.62)
Magnetic resonance imaging (MRI) 14 (4.3) 38 (3.9) 1.37 (0.71–2.62)
Nuclear imaging 50 (15.3) 174 (17.8) 1.07 (0.74–1.53)
Endoscopy 53 (16.2) 277 (28.4) 0.55 (0.39–0.77)
Medical procedures
Exploratory surgerya c c 1.36 (0.21–8.71)
Resection, non-surgicalb 290 (88.7) 882 (90.3) 1.05 (0.69–1.60)
Resection, surgical (non-cutaneous) 20 (6.1) 158 (16.2) 0.46 (0.28–0.75)
Resection, surgical (cutaneous) 27 (8.3) 68 (7.0) 1.12 (0.68–1.85)
Pathology tests
Serum tumor markers 126 (38.6) 327 (33.5) 1.36 (1.04–1.78)
Cytology without immunohistochemistry 112 (34.3) 256 (26.2) 1.78 (1.33–2.38)
Cytology with immunocytochemistry 25 (7.6) 36 (3.7) 2.54 (1.45–4.46)
Histopathology without immunohistochemistry 101 (30.9) 561 (57.4) 0.40 (0.29–0.53)
Histopathology with immunohistochemistry 59 (18.0) 252 (25.8) 0.77 (0.55–1.08)
Cytogenetics c c 5.11 (0.79–33.1)
a Exploratory surgery includes laparotomy, thoracotomy, and cervical exploration of mediastinum
b Non-surgical resection includes fine needle aspiration, biopsy or excision, other than regional or radical excision which has been classified as surgical resection
c Cell size <5; exact cell size suppressed for privacy reasons
https://doi.org/10.1371/journal.pone.0230373.t002
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notified with metastatic cancer of known origin. People with CUP were more likely to be in
aged care, and their pathway to diagnosis was more likely to involve an emergency presenta-
tion and the use of less invasive diagnostic tests. Many ED visits in people with cancer are
avoidable;[22] however, the use of less invasive diagnostic tests, for example imaging and fine
needle aspiration, may be appropriate for people who are frail (including many aged care resi-
dents [23]), or those with a poor prognosis, and this diagnostic pathway is supported by clini-
cal guidelines for CUP [14,21].
This is one of the first studies to identify an increased risk of a CUP diagnosis in aged care
residents.[8] Very few cohort studies have examined the association between aged care resi-
dency and cancer diagnosis as this information is not typically available at the population-
level. A US cancer-registry study of women insured by Medicaid observed a 2.5-fold excess
risk of late breast cancer diagnosis in women who were nursing home residents or were in a
long-term care facility.[24] A more recent US study[25] found that very few Medicaid-insured
nursing home patients received cancer services, and they exhibited a high prevalence of late or
unstaged common cancers. While these studies may not be generalizable to the Australian
context, it is known that on average, aged care residents are likely to be frail with potentially
complex multimorbidity and health care needs. In addition, they may not have close family
members to advocate on their behalf regarding changes in their health status. Frail patients
may not tolerate cancer treatment due to the increased risk of toxicity and mortality [26],
decreasing the need for comprehensive testing to identify the tissue of origin. Late diagnosis
may not necessarily be a marker of inadequate care in this setting, as it is possible that func-
tional impairment, care dependency, prognosis, and patient preferences were taken into
account when considering the most appropriate diagnostic management of people with meta-
static cancer of unknown origin, in keeping with clinical guidelines[13,21].
Confirming previous studies, we found that people with a cancer-registry CUP diagnosis
were nearly twice as likely to have had an ED visit in the time period immediately preceding
diagnosis, compared to people diagnosed with metastatic cancer of known primary. In our
study, 53% of people diagnosed with CUP had a recent ED visit, which is similar to previous
Australian studies (50–57%)[8,27] and a UK study of a national cancer registry (57%).[28]
Cancer diagnosis via ED presentation is considered a marker for late or delayed diagnosis,
and is generally associated with older age, greater deprivation, less access to health services,
and poorer prognosis.[29–31] However, the reasons for presentation via ED are complex and
many patients also have significant interaction with the health care system prior to their ED
presentation, which may represent lost opportunities for diagnosis in individuals with good
quality of life and life expectancy who are most likely to benefit from treatment.[31]
Table 3. Association between recent health service use, cancer-related diagnostic tests and procedures, and diag-
nosis of CUP compared to metastatic cancer of known primary.
Tests or procedures in month of diagnosis and three months prior Fully adjusted
OR (95% CI)a
Tertiary care
�1 emergency department visit 1.65 (1.23–2.21)
Aged care facility 2.78 (1.37–5.63)
Pathology tests
Serum tumor markers 1.51 (1.12–2.04)
Cytology without immunohistochemistry 2.01 (1.47–2.76)
Histopathology without immunohistochemistry 0.43 (0.31–0.59)
a Adjusted for age and educational attainment
https://doi.org/10.1371/journal.pone.0230373.t003
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While the reasons for ED presentation in people diagnosed with CUP are not known to us,
the non-specific and variable nature of CUP symptoms may lead to delayed diagnosis, even in
patients who regularly interact with the health care system. As such, we saw no difference
between CUP and metastatic cancer of known origin in terms of household income, rural resi-
dential location, hospitalisations, GP visits, or allied health visits in this cohort. Although this
replicates our previous findings in a veterans cohort,[8] we acknowledge that both studies had
limited statistical power, and suggest these associations deserve further scrutiny in large, well-
annotated cohorts. It is important to understand the reasons for ED presentation prior to diag-
nosis, and whether there were missed opportunities for earlier diagnosis, specifically through
earlier presentation to a GP, and identification of symptoms suggestive of cancer, leading to
suitable investigations.
Only a small proportion of cases and controls had no cancer-related investigations (6%);
however, the types of investigations between the two groups differed. People diagnosed with
CUP had a greater use of less invasive tests such as serum tumor markers and cytology, and
less use of histopathology, compared to controls. While the former are less invasive, the rou-
tine use of non-specific serum tumor markers is not recommended for patients with suspected
cancer because they can be overexpressed in some people without cancer.[13,32] While histo-
pathology is considered part of the diagnostic approach to identify the primary tumor in CUP
patients,[32] only 50% of registered CUP cases in our study were histopathologically verified.
This is lower than observed in other population-based studies of CUP[2,7,11,15,33] but higher
than our previous study in Australian veterans (36%).[8,15] CUP is a heterogeneous diagnosis,
and encompasses individuals who may have undergone exhaustive investigation but a primary
site cannot be identified (i.e. people with “true CUP”), and also individuals with a clinical diag-
nosis only, for whom invasive tests are neither warranted nor desired.[13] In a 2019 US study,
only 35% of elderly people with CUP received guideline recommended diagnostic evaluation.
[33] Patients with a clinical diagnosis only tend to be older, and have poorer outcomes.[7,8]
Unfortunately, we are unable to determine whether the diagnostic approach was clinically
appropriate; however, it is recommended that investigations considered to have no impact on
prognosis should be avoided.
The strength of this study is the comprehensiveness and quality of the data for a large, pro-
spective cohort; incident cancers and deaths were ascertained by high-quality population-based
registries, and we had near complete capture of all subsidized health service interactions for our
population, including community-based consultations and tertiary care, diagnostic tests and
procedures, as well as information on aged care. This allowed us to construct a comprehensive
picture of people’s health service use prior to cancer diagnosis. While our sample size is one of
the largest population-based studies of people with CUP[8,9], it is modest. As a result, we may
have had insufficient power to detect an association with some health services, and where we
did, the confidence intervals are wide. While 45 and Up Study participants are healthier on
average than the general population, relative estimates calculated from within-cohort compari-
sons are valid.[34,35] Two data issues are also unlikely to have affected our within-cohort com-
parisons; firstly, the ED data mainly captured visits to metropolitan and large regional public
hospitals (72% and 88% of ED presentations in NSW, respectively).[36,37] Secondly, some
pathology services will be under-ascertained as MBS claims data only capture the three most
expensive pathology items in an episode of care performed by a GP.[38]
People diagnosed with CUP represent people for whom the primary site could not be iden-
tified despite exhaustive testing, as well as those who received minimal diagnostic evaluation;
unfortunately we could not distinguish these two groups based on the cancer registry data
alone. Ideally, such distinct groups would receive distinguishable diagnoses, but this is not the
case. Given the improvement in diagnostics over time, it is likely that the prevalence of “true
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CUP” will decrease, with most people diagnosed with CUP representing those who did not
receive all clinically-indicated tests, and it is important that these people are not ignored in
cancer research. Finally, we have made the assumption that the identified procedures and tests
were diagnostic for cancer, but some procedures, particularly non-specific tests such as endos-
copy and ultrasound, may have been performed for other reasons. Importantly, we could not
directly measure frailty in our study. Frailty plays a role in health decisions and outcome, yet
is a concept that is difficult to capture in administrative claims data; while many studies have
tried they each have their limitations.[39,40] Our findings support the need for further
research to elucidate the relationship between frailty, health service utilisation, and CUP
diagnosis.
Conclusions
We have shown that people with a cancer-registry notified CUP diagnosis had a different path-
way to diagnosis than patients with metastatic cancer of known primary. People diagnosed
with CUP were more likely to be aged care residents, to have had an ED presentation immedi-
ately prior to diagnosis, and to have received fewer invasive tests. Interestingly, despite CUP
patients having poorer self-reported overall health,[18] the two groups exhibited no difference
in the likelihood of having at least one hospitalisation or consultation during the month of
diagnosis and three months prior. Further research is required to examine whether these
results indicate missed opportunities in CUP patients for earlier detection and diagnostic test-
ing to reveal the tissue of origin, or conversely represent clinically appropriate differences in
management based on patients’ underlying health and life expectancy.
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